AAL

Biotech Stock Scores Big Win, Squeezes Shorts

VRDN is still down 27% in 2024 despite today's double-digit pop

Managing Editor
Sep 10, 2024 at 10:58 AM
facebook X logo linkedin


Viridian Therapeutics Inc (NASDAQ:VRDN) stock is up 11.1% to trade at $15.75 today, and earlier traded as high as $16.35, after the biotech company's eye disorder treatment met the main goal of a late-stage study. VRDN is on track for its best single-session gain of 2024. 

Despite today's breakout, the shares are still 28% lower year to date, and momentum has fallen short of its 200-day moving average. A short squeeze could keep the wind at the equity's back though; short interest fell 7.3% in the two most recent reporting periods, yet the 8 million shares sold short still account for 12.9% of VRDN's total available float. At the stock's average pace of trading, it would take shorts nearly eight trading days to buy back their bearish bets. 

Put traders have been crowding Viridian as well. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows 6,000 puts were bought to open in the last 10 days, compared to just 460 calls. 

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.